Promise already turning into fact: management shows the thing it told investors was coming is now measurably arriving, a
The model's full reasoning — Q1 2016 call → NOWe need answer YES/NO based on transcript. Need identify pattern: prior expectation, current confirmation, still early. Let's analyze. Company Curis. Programs: CUDC-907 Phase 2 in DLBCL with MYC alterations. CA170 oral checkpoint inhibitor entering clinic. Erivedge royalties. Question asks: "On this call, does management point to a growth-bearing development in its business that IT HAD PREVIOUSLY TOLD INVESTORS TO EXPECT — and demonstrate, with real current-period activity, that this development is NOW ACTUALLY ARRIVING at or beyond the pace management had indicated, while ALSO conveying that the development is still early, with most of its contribution ahead?" Need find if management refers back to prior expectation, current activity confirming, and still early. Look at transcript. Ali Fattaey: "Our most advanced program is CUDC-907 and it is being tested in an ongoing Phase 2 clinical trial to treat patients with relapsed refractory DLBCL. As a reminder, last December at the ASH Conference, we presented results from our Phase 1 study of CUDC-907 as monotherapy where we enrolled 22 patients with relapsed refractory DLBCL and reported seven objective responses out of the 16 evaluable patients. As of today, we have now completed the enrollment in the monotherapy arm of the Phase 1 and of the total 25 patients in this arm of the study, eight patients have experienced an objective response out of the total 19 response evaluable patients. Note that this does not include the one complete response that we reported at the ASH Conference for patients with DLBCL that was treated with CUDC-907 in combination with rituximab in a separate expansion arm of the study. In addition, a retrospective analysis by us of the Phase 1 data indicates that the clinical benefit that we observed may be related to an inhibition of MYC oncogene as there was a correlation between patients who reported objective responses and their DLBCL tumors harboring alterations in the MYC oncogene. These alterations included MYC gene copy number gains or elevated levels of MYC protein in the tumor cells per criteria that have been set in the field.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| MCD | McDonald's Corporation | Q2 2024 | 2024-07-29 | D |
| AES | The AES Corporation | Q1 2024 | 2024-05-03 | C+ |
| ASB | Associated Banc-Corp | Q1 2024 | 2024-04-25 | A |
| DUOT | Duos Technologies Group, Inc. | Q4 2023 | 2024-04-01 | F |
| HP | Helmerich & Payne, Inc. | Q1 2024 | 2024-01-30 | C |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| SITM | SiTime Corporation | Q2 2023 | 2023-08-02 | C+ |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| XHR | Xenia Hotels & Resorts, Inc. | Q2 2022 | 2022-08-05 | A |
| BRKL | Brookline Bancorp, Inc. | Q2 2022 | 2022-07-30 | B+ |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| KD | Kyndryl Holdings, Inc. | Q4 2021 | 2022-03-01 | C+ |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| WES | Western Midstream Partners, LP | Q3 2018 | 2018-10-31 | D |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| AU | AngloGold Ashanti's | Q2 2018 | 2018-08-20 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| CNS | Cohen & Steers, Inc. | Q2 2017 | 2017-07-20 | B |
| PTC | PTC Inc. | Q3 2017 | 2017-07-19 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| PPG | PPG Industries, Inc. | Q1 2017 | 2017-04-20 | C |
| MDLZ | Mondelez International, Inc. | Q4 2016 | 2017-02-07 | C |
| BP | BP p.l.c. | Q4 2016 | 2017-02-07 | B+ |
| NTCT | NetScout Systems, Inc. | Q2 2017 | 2016-10-27 | D |
| F | Ford Motor Company | Q3 2016 | 2016-10-27 | B+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| NDSN | Nordson Corporation | Q3 2016 | 2016-08-23 | A |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| NWSA | News Corporation | Q2 2016 | 2016-08-08 | C+ |
| CGNX | Cognex Corporation | Q2 2016 | 2016-08-01 | A |
| TRV | The Travelers Companies, Inc. | Q2 2016 | 2016-07-21 | C+ |
| LBTYK | Liberty Global's | Q1 2016 | 2016-05-10 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
| DD | DuPont de Nemours, Inc. | Q1 2016 | 2016-04-26 | B+ |
| HD | The Home Depot, Inc. | Q4 2015 | 2016-02-23 | A |
| SAN | Banco Santander, S.A. | Q4 2015 | 2016-01-27 | B |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
ICFI · Q1 2017 → YESThe question is: Does management point to a growth-bearing development that they previously told investors to expect, and now it's arriving with current activity, but still early with most contributio...YES Management explicitly references the themes from their February 2017 full-year earnings call (only two months prior), noting that the January-February pickup they had highlighted there continued through March. They then point to concrete current-period activity: ICF Olson won over $75 million in new revenue since acquisition (neither firm could have won independently), added substantial new-account wins in Q1, and saw its qualified pipeline rise significantly above year-end 2016 levels. John Wasson confirms the new projects and retainers are now lining up, with strong Q1 wins and momentum from added staff. Sudhakar states they expect mid-single-digit growth this 2017 and sequential improvement, while reiterating confidence in the medium-term outlook. The language makes clear the ramp is still early—H2 comparisons and most of the contribution lie ahead—matching the three-part pattern for this growth-bearing development. No other item in the call satisfies all three criteria as cleanly.
HOLX · Q4 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES The transcript shows a clear three-part pattern for international growth. Management explicitly references its prior expectation: “while we thought that international would be a double-digit grower by 2018, we've actually delivered on that promise a year earlier than anticipated.” In the just-reported Q4, they confirm the development with concrete activity 17.5% international growth (excluding Cynosure and blood), the sixth consecutive quarter of double-digit growth for molecular internationally, and Panther shipments exceeding prior-year levels. They also state it is still early with most contribution ahead: “we've actually delivered on that promise a year earlier,” and they hope investors remember this 2017 success story as they evaluate Cynosure 2.
PTC · Q3 2017 → YESThe question is about whether management points to a growth-bearing development they previously told investors to expect, and now it's arriving with current activity, but still early. YES Management explicitly references its prior long-term growth ambition for IoT (30-40% bookings growth, consistent with the faster-growing IoT market) as part of its double-digit overall plan, which it had communicated as the target to achieve sustainable growth. In the current quarter, it confirms this is materializing with 40%+ of IoT bookings from customer expansions, six-figure deals growing sequentially and year-over-year, and specific closed expansions with leading food/beverage, aerospace/defense, and medical device companies, plus strong contribution from these. It further conveys the development remains early by noting customers are "generally still in the early days of their IoT journeys" with "adoption is gaining momentum" and "further stages" (e.g.